Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers.177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, isan antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.

Biotechnology

Health Care

Therapeutics

Ariceum Therapeutics

Manfred Ruediger

Greg Mullen, PhD, FRSC

Serge SAGODIRA

Marion H.

Manuel Sturzbecher-Hoehne

Germo Gericke

Dennis MEWIS

Anika Jäkel

The Leadership Team at Ariceum Therapeutics is responsible for setting the strategic direction and overseeing the overall operations of the company. This team brings together expertise in clinical development, medical affairs, business operations, and executive leadership to drive innovation in radiopharmaceutical therapies. By collaborating closely, they ensure the successful advancement of satoreotide and other projects aimed at improving diagnosis and treatment options for patients with aggressive cancers.

Leadership Team

Clinical Development Team

Leadership Team

About

Team members

Other teams at Ariceum Therapeutics

Clinical Development Team